| David G Hutchins, DPM | |
|
112 River Rd, Chelsea, ME 04330-1009 | |
| (207) 622-2102 | |
| (207) 622-2102 |
| Full Name | David G Hutchins |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 49 Years |
| Location | 112 River Rd, Chelsea, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306068093 | NPI | - | NPPES |
| H222001 | Other | ME | BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213EP1101X | Podiatrist - Primary Podiatric Medicine | 139 (Maine) | Primary |
| Provider Name | State Of Maine |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1699776146 PECOS PAC ID: 7517875131 Enrollment ID: O20040610001611 |
News Archive
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
The annual Society for Endocrinology BES conference is taking place in Harrogate, UK from 19-22 March 2012.
Starting this month Canadian and British scientists will begin collaborating on a study to examine human appetite- controlling hormones with a view to finding out what will increase PYY, a powerful hormone in the human body which dramatically diminishes appetite.
One in 10 heart failure patients had compression fractures in the spine that could have been detected by a chest X-ray, but few are receiving treatment to help prevent such fractures according to a Canadian study published in the American Heart Association journal Circulation: Heart Failure.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David G Hutchins, DPM 112 River Rd, Chelsea, ME 04330-1009 Ph: (207) 622-2102 | David G Hutchins, DPM 112 River Rd, Chelsea, ME 04330-1009 Ph: (207) 622-2102 |
News Archive
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
The annual Society for Endocrinology BES conference is taking place in Harrogate, UK from 19-22 March 2012.
Starting this month Canadian and British scientists will begin collaborating on a study to examine human appetite- controlling hormones with a view to finding out what will increase PYY, a powerful hormone in the human body which dramatically diminishes appetite.
One in 10 heart failure patients had compression fractures in the spine that could have been detected by a chest X-ray, but few are receiving treatment to help prevent such fractures according to a Canadian study published in the American Heart Association journal Circulation: Heart Failure.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
› Verified 8 days ago